ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Lexeo Therapeutics Inc

Lexeo Therapeutics Inc (LXEO)

2.70
-0.11
(-3.91%)
Closed March 08 4:00PM
2.705
0.005
(0.19%)
After Hours: 7:59PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.70
Bid
2.70
Ask
10.00
Volume
294,177
2.69 Day's Range 2.95
2.32 52 Week Range 19.50
Market Cap
Previous Close
2.81
Open
2.80
Last Trade
1
@
2.7
Last Trade Time
Financial Volume
$ 817,936
VWAP
2.7804
Average Volume (3m)
313,554
Shares Outstanding
33,065,947
Dividend Yield
-
PE Ratio
-1.34
Earnings Per Share (EPS)
-2.01
Revenue
-
Net Profit
-66.39M

About Lexeo Therapeutics Inc

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t... Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Lexeo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker LXEO. The last closing price for Lexeo Therapeutics was $2.81. Over the last year, Lexeo Therapeutics shares have traded in a share price range of $ 2.32 to $ 19.50.

Lexeo Therapeutics currently has 33,065,947 shares outstanding. The market capitalization of Lexeo Therapeutics is $92.92 million. Lexeo Therapeutics has a price to earnings ratio (PE ratio) of -1.34.

LXEO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3-1033.38382.329617512.58692261CS
4-2.63-49.34333958725.335.542.325312563.31779324CS
12-4.31-61.48359486457.017.662.323135544.42886188CS
26-8.1-7510.811.722.323734107.02201302CS
52-12.17-81.842636180214.8719.52.322966189.6673827CS
156-6.8-71.57894736849.522.332.3225025210.10676767CS
260-6.8-71.57894736849.522.332.3225025210.10676767CS

LXEO - Frequently Asked Questions (FAQ)

What is the current Lexeo Therapeutics share price?
The current share price of Lexeo Therapeutics is $ 2.70
How many Lexeo Therapeutics shares are in issue?
Lexeo Therapeutics has 33,065,947 shares in issue
What is the market cap of Lexeo Therapeutics?
The market capitalisation of Lexeo Therapeutics is USD 92.92M
What is the 1 year trading range for Lexeo Therapeutics share price?
Lexeo Therapeutics has traded in the range of $ 2.32 to $ 19.50 during the past year
What is the PE ratio of Lexeo Therapeutics?
The price to earnings ratio of Lexeo Therapeutics is -1.34
What is the reporting currency for Lexeo Therapeutics?
Lexeo Therapeutics reports financial results in USD
What is the latest annual profit for Lexeo Therapeutics?
The latest annual profit of Lexeo Therapeutics is USD -66.39M
What is the registered address of Lexeo Therapeutics?
The registered address for Lexeo Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Lexeo Therapeutics website address?
The website address for Lexeo Therapeutics is www.lexeotx.com
Which industry sector does Lexeo Therapeutics operate in?
Lexeo Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ABLVAble View Global Inc
$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
$ 6.96
(-36.15%)
570.43k
SCNXScienture Holdings Inc
$ 1.55
(-35.68%)
1.54M
ACXPAcurx Pharmaceuticals Inc
$ 0.4572
(-29.88%)
1.13M
RETOReTo Eco Solutions Inc
$ 5.42
(-27.73%)
108k
OCTOEightco Holdings Inc
$ 1.08
(-27.03%)
332.1k
BTOGBit Origin Ltd
$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
$ 0.169898
(17.17%)
142.23M

Your Recent History

Delayed Upgrade Clock